Swordsmyth
Member
- Joined
- Apr 14, 2016
- Messages
- 74,737
In a major policy shift, the FDA has announced it will no longer approve annual COVID-19 vaccines for healthy children and adults under 65. Going forward, yearly boosters will be reserved primarily for seniors and individuals with underlying health conditions, marking a significant rollback of the universal vaccination approach used during the pandemic.
According to FDA officials, the updated guidance reflects evolving data showing that the benefit of routine boosters for low-risk individuals is minimal. In contrast, evidence continues to support annual vaccination for those over 65 and others with elevated medical risk—such as individuals with diabetes, heart disease, cancer, or weakened immune systems.
“The science doesn’t support giving healthy 25-year-olds a shot every year,” one senior FDA official said. “We’re narrowing the focus to where the data clearly show a benefit: older adults and high-risk groups.”
Pharmaceutical companies like Pfizer and Moderna will now be required to present new, robust clinical trial data before the FDA considers approving updated annual boosters for younger populations. These trials will need to demonstrate that boosters significantly reduce serious illness, hospitalizations, or deaths in otherwise healthy individuals—something existing data has yet to clearly establish.
More at:
www.realnewsnow.com
According to FDA officials, the updated guidance reflects evolving data showing that the benefit of routine boosters for low-risk individuals is minimal. In contrast, evidence continues to support annual vaccination for those over 65 and others with elevated medical risk—such as individuals with diabetes, heart disease, cancer, or weakened immune systems.
“The science doesn’t support giving healthy 25-year-olds a shot every year,” one senior FDA official said. “We’re narrowing the focus to where the data clearly show a benefit: older adults and high-risk groups.”
Pharmaceutical companies like Pfizer and Moderna will now be required to present new, robust clinical trial data before the FDA considers approving updated annual boosters for younger populations. These trials will need to demonstrate that boosters significantly reduce serious illness, hospitalizations, or deaths in otherwise healthy individuals—something existing data has yet to clearly establish.
More at:
Code:
https://www.realnewsnow.com/fda-will-no-longer-approve-annual-covid-vaccine-for-younger-healthy-patients/FDA Will No Longer Approve Annual COVID Vaccine For Younger, Healthy Patients - Real News Now
In a major policy shift, the FDA has announced it will no longer approve annual COVID-19 vaccines for healthy children and adults under 65. Going forward, yearly boosters will be reserved primarily for seniors and individuals with underlying health conditions, marking a significant rollback of...
www.realnewsnow.com
